Trial record 1 of 2 for:    cabazitaxel prednisone custirsen
Previous Study | Return to List | Next Study

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by OncoGenex Technologies
Sponsor:
Collaborator:
Teva Pharmaceutical Industries
Information provided by (Responsible Party):
OncoGenex Technologies
ClinicalTrials.gov Identifier:
NCT01578655
First received: April 9, 2012
Last updated: April 10, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)